S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:GRCL

Gracell Biotechnologies Stock Forecast, Price & News

$6.84
-0.27 (-3.80%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.51
$7.05
50-Day Range
$6.38
$14.90
52-Week Range
$5.86
$33.70
Volume
439,214 shs
Average Volume
1.33 million shs
Market Capitalization
$461.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive GRCL News and Ratings via Email

Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.


Gracell Biotechnologies logo

About Gracell Biotechnologies

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

Headlines

Gracell Biotechnologies (NASDAQ:GRCL) Trading Down 3%
December 1, 2021 |  americanbankingnews.com
Gracell Biotechnologies (NASDAQ:GRCL) Trading Up 4.1%
November 30, 2021 |  americanbankingnews.com
Gracell Biotechnologies (NASDAQ:GRCL) Trading 27.1% Higher
November 23, 2021 |  americanbankingnews.com
Gracell Biotechnologies (NASDAQ:GRCL) Hits New 52-Week Low at $8.27
November 19, 2021 |  americanbankingnews.com
Gracell Biotechnologies (NASDAQ:GRCL) Shares Down 13.3%
November 18, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRCL
Fax
N/A
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.54 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$461.70 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/14/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/08/2022

MarketRank

Overall MarketRank

1.45 out of 5 stars

Medical Sector

1095th out of 1,390 stocks

Pharmaceutical Preparations Industry

517th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Gracell Biotechnologies (NASDAQ:GRCL) Frequently Asked Questions

Is Gracell Biotechnologies a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Gracell Biotechnologies stock.
View analyst ratings for Gracell Biotechnologies
or view top-rated stocks.

Are investors shorting Gracell Biotechnologies?

Gracell Biotechnologies saw a decrease in short interest in October. As of October 29th, there was short interest totaling 634,200 shares, a decrease of 23.0% from the October 14th total of 823,400 shares. Based on an average daily trading volume, of 81,200 shares, the short-interest ratio is currently 7.8 days. Currently, 1.1% of the shares of the company are short sold.
View Gracell Biotechnologies' Short Interest
.

When is Gracell Biotechnologies' next earnings date?

Gracell Biotechnologies is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Gracell Biotechnologies
.

How were Gracell Biotechnologies' earnings last quarter?

Gracell Biotechnologies Inc. (NASDAQ:GRCL) posted its quarterly earnings results on Sunday, November, 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.18.
View Gracell Biotechnologies' earnings history
.

What price target have analysts set for GRCL?

4 brokers have issued 12 month price targets for Gracell Biotechnologies' stock. Their forecasts range from $30.00 to $40.00. On average, they expect Gracell Biotechnologies' share price to reach $34.50 in the next year. This suggests a possible upside of 404.4% from the stock's current price.
View analysts' price targets for Gracell Biotechnologies
or view top-rated stocks among Wall Street analysts.

Who are Gracell Biotechnologies' key executives?

Gracell Biotechnologies' management team includes the following people:
  • Dr. Wei Cao, Founder, Chairman & CEO (Age 62)
  • Dr. Yili Xie M.B.A., Ph.D., Chief Financial Officer (Age 50)
  • Dr. Yajin Ni, Chief Technology Officer
  • Dr. Martina A. Sersch M.D., Ph.D., Chief Medical Officer (Age 48)

When did Gracell Biotechnologies IPO?

(GRCL) raised $150 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO.

What is Gracell Biotechnologies' stock symbol?

Gracell Biotechnologies trades on the NASDAQ under the ticker symbol "GRCL."

Who are Gracell Biotechnologies' major shareholders?

Gracell Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Temasek Holdings Private Ltd (14.73%), Wellington Management Group LLP (7.38%), Viking Global Investors LP (2.02%), Morgan Stanley (1.43%), BlackRock Inc. (1.39%) and Capital International Sarl (0.24%).

Which institutional investors are selling Gracell Biotechnologies stock?

GRCL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., Citadel Advisors LLC, and Marshall Wace LLP.

Which institutional investors are buying Gracell Biotechnologies stock?

GRCL stock was acquired by a variety of institutional investors in the last quarter, including Temasek Holdings Private Ltd, Wellington Management Group LLP, Viking Global Investors LP, Vident Investment Advisory LLC, Capital International Sarl, and Daiwa Securities Group Inc..

How do I buy shares of Gracell Biotechnologies?

Shares of GRCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gracell Biotechnologies' stock price today?

One share of GRCL stock can currently be purchased for approximately $6.84.

How much money does Gracell Biotechnologies make?

Gracell Biotechnologies has a market capitalization of $461.70 million.

How many employees does Gracell Biotechnologies have?

Gracell Biotechnologies employs 2,020 workers across the globe.

What is Gracell Biotechnologies' official website?

The official website for Gracell Biotechnologies is www.gracellbio.com.

How can I contact Gracell Biotechnologies?

The company can be reached via phone at 86-512-6262-6701 or via email at [email protected].


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.